Efficacy and Safety in Patients With Acute Coronary Syndrome Without ST-Segment Elevation

Double-Blind Parallel Comparison Study of SR25990C Versus Standard Therapy in Japan(Ticlopidine) in Patients With Acute Coronary Syndrome Without ST-Segment Elevation Who Are Planned for Percutaneous Coronary Intervention

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00325390

Enrollment

800

Registered

2006-05-12

Start date

2004-07-31

Completion date

Unknown

Last updated

2009-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

NSTEACS, Platelet Aggregation Inhibitors

Keywords

SR25990C, Platelet Aggregation Inhibitors, NSTEACS

Brief summary

To evaluate the efficasy and safety of SR25990C(loading dose:300mg, maintenance dose:75mg/day) in comparison with the standard Japanese treatment(ticlopidine) in patients with acute coronary syndrome without ST-segment elevation and planned for percutaneous coronary intervention(including stenting).

Interventions

DRUGclopidogrel (SR25990C)

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

20 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients aged above 20, admitted to hospitals with symptoms suspected to represent an acute coronary syndrome defined as unstable angina or acute MI without ST segment elevation greater than 1 mm are eligible for the study if they meet the following criteria: * (1)Clinical history consistent with new onset or worsening pattern of characteristic ischemic chest pain occurring at rest or with minimal exercise (lasting longer than 5 minutes or requiring sublingual nitroglycerin for the relief of pain within 24 hours before registration). * (2)Patients who meet either of following criteria * ECG changes compatible with new ischemia \[e.g. ST depression (at least 1 mm), T wave inversion (at least 2 mm), or hyperacute peaked T waves in 2 contiguous leads\]. * already elevated CK at least twice the upper limit of normal or CK-MB or Troponin I or T above the upper limit of normal or positive qualitative test for Troponin T. * (3)A percutaneous coronary intervention is planned within 96 hours after the first study drug administration

Exclusion criteria

* A)Factors that affect participation in study: * (1)Previous disabling stroke * (2)Previous intracranial hemorrhage or hemorrhagic stroke * (3)Severe co-morbid condition such that the patient is not expected to survive 1 month * (4)NYHA Class IV heart failure * (5)Uncontrolled hypertension * (6)Requirement for use of oral anticoagulants, non study antiplatelet agents (including ticlopidine) or NSAIDs (excluding unum sumatur), during study period, * B)Factors related to ASA and/or ticlopidine treatment: * (1)Use of ticlopidine within 1 week prior to randomization * (2)History of ASA or ticlopidine intolerance or allergy * (3)Contraindications to ASA or ticlopidine

Design outcomes

Primary

Measure	Time frame
Incidence of effficacy and safety events	—

Secondary

Measure	Time frame
Incidence of efficacy or safety events, adverse events, adverse drug reactions and bleeding events・	—

Countries

Japan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026